Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
-
Adolescent
-
Adolescent
-
Adult
-
Adult
-
Aged
-
Aged
-
Antibodies, Antinuclear
-
Antibodies, Antinuclear
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
Autoantibodies
-
Autoantibodies
-
B-Cell Activating Factor
-
B-Cell Activating Factor
-
Biomarkers
-
Biomarkers
-
B-Lymphocytes
-
B-Lymphocytes
-
Complement C3
-
Complement C3
-
Complement C4
-
Complement C4
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Administration Schedule
-
Female
-
Female
-
Humans
-
Humans
-
Injections, Subcutaneous
-
Injections, Subcutaneous
-
Lupus Erythematosus, Systemic
-
Lupus Erythematosus, Systemic
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Severity of Illness Index
-
Severity of Illness Index
-
Treatment Outcome
-
Treatment Outcome
-
Young Adult
-
Young Adult